Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazarotene/Halobetasol Lotion for Scalp Psoriasis
NCT05872256Phase 4Completed
- Sponsor
- Dermatology Consulting Services
- Start
- Jun 2023
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tazarotene and Halobetasol propionate 0.05% lotion in psoriasis, sponsored by Dermatology Consulting Services. Primary endpoints: Hair Growth at 12 weeks and Scalp Itch at 12 weeks. Started Jun 2023; status: completed.
02
Drugs
tazaroteneHalobetasol propionate 0.05% lotion
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT05872256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05872256.